Praxis Precision Medicines Inc. announced that the U.S. Food and Drug Administration has agreed to the company's proposed changes to the EMBRAVE3 registrational trial for elsunersen in early-onset SCN2A developmental and epileptic encephalopathy (DEE). The trial has been converted from a double-blind, sham-controlled design to a single-arm, baseline-controlled study, reducing the enrollment target from 40 to 30 patients. All participants will receive elsunersen for 24 weeks, followed by an open-label extension. The primary analysis will focus on the change from baseline in countable motor seizures. Enrollment in EMBRAVE3 is accelerating, with topline results expected in 2026. Additionally, topline results from the ongoing EMBRAVE study (Part A, n=9) are anticipated in the first half of 2026. No study results have been presented yet.